Structural and biophysical insights into targeting of claudin-4 by a synthetic antibody fragment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Structural and biophysical insights into targeting of claudin-4 by a synthetic antibody fragment ; volume:7 ; number:1 ; day:17 ; month:6 ; year:2024 ; pages:1-16 ; date:12.2024
Communications biology ; 7, Heft 1 (17.6.2024), 1-16, 12.2024
- Creator
-
Erramilli, Satchal K.
Dominik, Pawel K.
Ogbu, Chinemerem P.
Kossiakoff, Anthony A.
Vecchio, Alex J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s42003-024-06437-6
- URN
-
urn:nbn:de:101:1-2408271311175.537358010632
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.20252025, 11:11 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Erramilli, Satchal K.
- Dominik, Pawel K.
- Ogbu, Chinemerem P.
- Kossiakoff, Anthony A.
- Vecchio, Alex J.
- SpringerLink (Online service)
Other Objects (12)
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
Synthetic Sphingolipid analogues biophysical properties and subcellular localization
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses
Structural and biophysical characterization of antibody:antigen complexes of therapeutic relevance
Structural And Biophysical Characterization of Antibody-Antigen Complexes of Therapeutic Relevance
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
Liposomes targeting the cancer cell-exposed receptor, claudin-4, for pancreatic cancer chemotherapy
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
Synthetic Sphingolipid analogues biophysical properties and subcellular localization
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses
Structural and biophysical characterization of antibody:antigen complexes of therapeutic relevance
Structural And Biophysical Characterization of Antibody-Antigen Complexes of Therapeutic Relevance
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
Liposomes targeting the cancer cell-exposed receptor, claudin-4, for pancreatic cancer chemotherapy
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
Synthetic Sphingolipid analogues biophysical properties and subcellular localization
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses
Structural and biophysical characterization of antibody:antigen complexes of therapeutic relevance
Structural And Biophysical Characterization of Antibody-Antigen Complexes of Therapeutic Relevance
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting